Clorox Company (NYSE: CLX) witnessed a modest 1.3% decline in its stock price, closing at $93.06 on Friday, following the announcement of a recall involving 6.3 million units of scented cleaners. The recall, disclosed by the U.S. Consumer Product Safety Commission (CPSC) on September 3, 2026, affects only Mistolin and Lestoil products sold in Puerto Rico and the U.S. Virgin Islands. Despite the large number of bottles, the market's reaction was surprisingly subdued, reflecting investor confidence that the issue may be contained.
The recall stems from potential contamination with Pseudomonas aeruginosa, a bacterium that can pose serious risks to individuals with weakened immune systems or those using external medical devices. For healthy individuals, the risk is minimal, according to the CPSC notice. The affected products carry date codes beginning with “PR01” and ending between 25091 and 26168, corresponding to production from April 1, 2025, through June 17, 2026. Bottle sizes range from 28 to 128 fluid ounces.
Consumers are entitled to a full refund with a receipt, or the manufacturer's suggested retail price without one. However, Clorox has not disclosed the price mix, expected claim rate, or current channel inventory, leaving the financial impact uncertain. The company has not yet announced any provision for recall-related costs, which could be substantial if claim rates are high.
Interestingly, the stock had already been declining prior to the recall notice. From August 25 to September 2, CLX shares fell from $104.93 to $94.27, and by September 4, they had dropped further to $93.06. The recall notice came on September 3, after most of the decline had already occurred. On the day of the notice, the stock actually gained two cents, suggesting that the market had largely priced in the negative news.
Clorox's financial performance has been under pressure even before this recall. In fiscal 2026, net sales declined 5% to $6.72 billion, adjusted earnings per share fell 28% to $5.53, and operating cash flow dropped 38% to $612 million. The fourth-quarter gross margin contracted by 520 basis points to 41.3%, driven by lower volume, acquisition accounting, raw material costs, and logistics. These factors indicate that the company was already facing headwinds, and the recall adds another layer of complexity.
Management's guidance for fiscal 2027 projects net sales growth of 13% to 14%, with the GOJO acquisition contributing about 9.5 percentage points. Organic sales are expected to rise 3.5% to 4.5%, with more than 3.5 points coming from an easier ERP comparison. Adjusted EPS guidance ranges from $5.70 to $6.00, with a midpoint of $5.85, slightly below the analyst consensus of $5.97. A material recall charge could further pressure this gap, though Clorox has not revised its guidance.
The market's reaction suggests that investors are taking a wait-and-see approach. Key checkpoints include the NYSE reopening on Tuesday, September 8, after the Labor Day holiday, and management's appearance at the Barclays conference on Wednesday, September 9, where CEO Linda Rendle and CFO Luc Bellet are scheduled to speak. Any expansion of the recall, additional injuries, or a disclosed provision would likely trigger a more significant market response.
For now, the recall's scope appears limited to two territories, specific scents, and a defined production window, with no reported injuries. This containment gives Clorox a manageable path forward. However, if the recall expands or claims emerge, the financial and reputational damage could escalate. The next few weeks will be critical in determining whether Clorox can keep the problem under control.
